Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Neutral
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9629.5566
Address
Level 15 500 Collins Street Melbourne, Victoria (VIC) 3000
Description
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.21 - 0.76
Trade Value (12mth)
AU$70,151.00
1 week
-6.12%
1 month
-2.13%
YTD
-48.31%
1 year
-63.62%
All time high
4.35
EPS 3 yr Growth
20.30%
EBITDA Margin
%
Operating Cashflow
-$66m
Free Cash Flow Return
-169.40%
ROIC
-150.70%
Interest Coverage
-4,477.80
Quick Ratio
7.20
Shares on Issue (Fully Dilluted)
350m
HALO Sector
Healthcare
Next Company Report Date
22-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.96
Date | Announcements |
---|---|
03 September 24 |
Notice of release of escrowed securities
×
Notice of release of escrowed securities |
30 August 24 |
Appendix 4E and 2024 Annual Report
×
Appendix 4E and 2024 Annual Report |
30 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
31 July 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
22 May 24 |
Change in substantial holding
×
Change in substantial holding |
20 May 24 |
Application for quotation of securities - PAR
×
Application for quotation of securities - PAR |
30 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
26 April 24 |
Notification of cessation of securities - PAR
×
Notification of cessation of securities - PAR |
19 April 24 |
Type D Response Submitted and Received by the US FDA
×
Type D Response Submitted and Received by the US FDA |
05 April 24 |
Notification of cessation of securities - PAR
×
Notification of cessation of securities - PAR |
20 March 24 |
PAR to present at NWR Healthcare Conference
×
PAR to present at NWR Healthcare Conference |
08 March 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
08 March 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
06 March 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
04 March 24 |
Paradigm Board Changes
×
Paradigm Board Changes |
04 March 24 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
29 February 24 |
PAR Employee Performance Rights Plan Issue
×
PAR Employee Performance Rights Plan Issue |
29 February 24 |
Notification regarding unquoted securities - PAR
×
Notification regarding unquoted securities - PAR |
28 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
13 February 24 |
Notification regarding unquoted securities - PAR
×
Notification regarding unquoted securities - PAR |
12 February 24 |
Proposed issue of securities - PAR
×
Proposed issue of securities - PAR |
09 February 24 |
Primary Endpoint Achieved in Phase 2 MPS VI Trial
×
Primary Endpoint Achieved in Phase 2 MPS VI Trial |
09 February 24 |
PAR Appoints Business Development Consultant
×
PAR Appoints Business Development Consultant |
07 February 24 |
Paradigm Receives $7.36m R&D Tax Incentive Refund
×
Paradigm Receives $7.36m R&D Tax Incentive Refund |
31 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.